![](https://www. tiprank</a></h2>
<div class="post-meta">
<span class="author">
<i class="fa fa-user"></i>
<a href="https://blog.tipranks.com/author/thefly/" title="Posts by TheFly" rel="author">TheFly</a> </span>
<span class="date">
<i class="fa fa-calendar-o"></i>
<!-- <a href=""> </a>-->
November 1, 2024 </span>
</div>
<div class="post-entry">
<p>.com/stocks/slxn’ target= ‘_blank’; rel=’nofollow’>SLXN) עם דירוג קנייה ומחיר יעד של 30 סנט. החברה עדיין נמצאת מספר שנים מהשגת נתונים וממסחור SIL-204, שהיא גרסה מעודכנת של טיפול ה-LODER הקודם שלה. עם</p>
<div><a class="permalink" href="https://blog.tipranks.com/maxim-%d7%94%d7%aa%d7%97%d7%99%d7%9c%d7%95-%d7%9c%d7%a1%d7%a7%d7%a8-%d7%90%d7%aa-silexion-therapeutics-2/">Read More…</a></div>
</div>
</article>
<!-- end post -->
<!-- start post -->
<article class="post-wrap col-sm-6 post-1484364 post type-post status-publish format-standard has-post-thumbnail hentry category-blurbs tag-bmy tag-data-blurbs-report-quote tag-debrm tag-gb0r1f tag-it1bmy">
<div class="featured-media">
<a href="https://blog.tipranks.com/bristol-myers-squibb-sell-rating-due-to-mixed-financial-outlook-and-long-term-challenges/">
<div class="image-container" style="background-image: url(https://blog.tipranks.com/wp-content/uploads/2022/10/shutterstock_2161205029.jpg);">
</div>
</a>
<div class="category-list">
<ul class="post-categories">
<li><a href="https://blog.tipranks.com/tipranks-website/blurbs/" rel="category tag">Blurbs</a></li></ul> </div>
</div>
<h2 class="title h3"><a href="https://blog.tipranks.com/bristol-myers-squibb-sell-rating-due-to-mixed-financial-outlook-and-long-term-challenges/">Bristol-Myers Squibb: Sell Rating Due to Mixed Financial Outlook and Long-Term Challenges</a></h2>
<div class="post-meta">
<span class="author">
<i class="fa fa-user"></i>
<a href="https://blog.tipranks.com/author/christine/" title="Posts by Christine Brown" rel="author">Christine Brown</a> </span>
<span class="date">
<i class="fa fa-calendar-o"></i>
<!-- <a href=""> </a>-->
November 1, 2024 </span>
</div>
<div class="post-entry">
<p>Analyst Terence Flynn from Morgan Stanley reiterated a Sell rating on Bristol-Myers Squibb (BMY – Research Report) and decreased the price target to $36.00 from $37.00. Terence Flynn has given</p>
<div><a class="permalink" href="https://blog.tipranks.com/bristol-myers-squibb-sell-rating-due-to-mixed-financial-outlook-and-long-term-challenges/">Read More…</a></div>
</div>
</article>
<!-- end post -->
<!-- start post -->
<article class="post-wrap col-sm-6 post-1484292 post type-post status-publish format-standard hentry category-blurbs tag-bmy tag-sem">
<div class="featured-media no-image">
<div class="category-list">
<ul class="post-categories">
<li><a href="https://blog.tipranks.com/tipranks-website/blurbs/" rel="category tag">Blurbs</a></li></ul> </div>
</div>
<h2 class="title h3"><a href="https://blog.tipranks.com/analysts-offer-insights-on-healthcare-companies-select-medical-sem-and-bristol-myers-squibb-bmy/">Analysts Offer Insights on Healthcare Companies: Select Medical (SEM) and Bristol-Myers Squibb (BMY)</a></h2>
<div class="post-meta">
<span class="author">
<i class="fa fa-user"></i>
<a href="https://blog.tipranks.com/author/howard-kim/" title="Posts by Howard Kim" rel="author">Howard Kim</a> </span>
<span class="date">
<i class="fa fa-calendar-o"></i>
<!-- <a href=""> </a>-->
November 1, 2024 </span>
</div>
<div class="post-entry">
<p>Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Select Medical (<span class=){kind=link}
Maxim initiated coverage of Silexion Therapeutics (SLXN) with a Buy rating and 30c price target. The company is several years away from data and commercialization in developing SIL-204, an updated
Maxim התחילו לסקר את Silexion Therapeutics (SEM – Research Report) and Bristol-Myers Squibb (BMY – Research Report).
Select Medical (SEM)
Benchmark Co. analyst Bill Sutherland maintained a Buy rating on Select Medical today and set a price target of $48.00. The company’s shares closed last Thursday at $32.08.
According to TipRanks.com, Sutherland is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Select Medical is a Strong Buy with an average price target of $44.25.
See the top stocks recommended by analysts >>
Bristol-Myers Squibb (BMY)
In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Bristol-Myers Squibb, with a price target of $59.00. The company’s shares closed last Thursday at $55.77, close to its 52-week high of $56.20.
According to TipRanks.com, Scala is a 4-star analyst with an average return of
Bristol-Myers Squibb has an analyst consensus of Hold, with a price target consensus of $53.21, a -1.1% downside from current levels. In a report issued on October 17, Bernstein also initiated coverage with a Hold rating on the stock with a $56.00 price target.
Read More on SEM:
- Select Medical reports Q3 adjusted EPS 50c, consensus 43c
- Select Medical narrows FY24 adjusted EPS view to $2.09-$2.20 from $1.96-$2.20
- SEM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Select Medical, SSM form JV partnership to operate inpatient rehab hospital
- Select Medical to acquire Valir Rehabilitation Hospital, terms not disclosed